CAN:s bibliotek

*000      am
*00113960
*008070120|2003|||||||||||e||||||||||0|eng|d
*24510$aBuprenorphine and Buprenorphine/Naloxone :$ba guide for clinicians
*260  $aAmsterdam :$bElsevier,$c2003$y2003
*300  $a104 s :$bill.
*500  $aPER : Drug and alcohol dependence 70(2003):2 supplement
*520  $aFrom morphine clinics to buprenorphine regulating opoid agonist treatment of addiction in the United States. The clinical pharmacology of buprenorphine extrapolating from the laboratory of the clinic. Clinical and pharmacological evaluation of buprenorphine and naloxone combination: why the 4:1 ratio for treatment? Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Clinical efficacy of buprenorphine comparisons to methadone and placebo. Buprenorphine: how to use it right. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Accessing opiate-dependence treatment medications: buprenorphine products in an office-based setting. (From the table of contents)
*650 4$aBuprenorphine
*650 4$aNaloxone
*650 4$aPharmacology
*650 4$aUnited States
*650 4$aPregnancy
*650 4$aInfant, newborn
*650 4$aReview
*653  $aBuprenorfin
*653  $aFarmakologi
*653  $aUSA
*653  $aGraviditet
*653  $aNyfödda
*653  $aÖversikt
*7001 $aFudala, Paul J.$eguest ed.
*7001 $aBridge, Peter T.$eguest ed.
^